Story · Medicine & Biotech

FDA approves polatuzumab vedotin-piiq for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

1 outlet · first reported by FDA Drug Safety / Drugs feed 1d ago

Coverage, in order

  1. 1d ago
    FDA Drug Safety / Drugs feed indie
    FDA approves polatuzumab vedotin-piiq for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

    On April 19, 2023, the Food and Drug Administration approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specif

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.